‘Say no more’ to yeast infections: Scynexis rolls out new Brexafemme marketing — and rallying cry
Scynexis is rolling out a new campaign for its Brexafemme yeast infection treatment, but the effort is more than just advertising.
As CEO Marco Taglietti said in wrapping his prepared comments during an earnings call on Thursday, “Let me finish with our new rallying cry — yeast infection, say no more.”
That headline — written as “Yeast infection? Say no more” — appears on Scynexis’ recently launched ad campaign to healthcare providers and will begin rolling out to consumers later this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.